Kasum Miro, von Wolff Michael, Franulić Daniela, Čehić Ermin, Klepac-Pulanić Tajana, Orešković Slavko, Juras Josip
a Department of Obstetrics and Gynaecology , University Hospital Centre Zagreb, School of Medicine, University of Zagreb , Zagreb , Croatia .
b Division of Gynaecological Endocrinology and Reproductive Medicine , Women's Hospital, University of Berne , Berne , Switzerland .
Gynecol Endocrinol. 2015;31(11):846-51. doi: 10.3109/09513590.2015.1081684. Epub 2015 Sep 15.
The purpose of this review is to analyse current options for fertility preservation in young women with breast cancer (BC). Considering an increasing number of BC survivors, owing to improvements in cancer treatment and delaying of childbearing, fertility preservation appears to be an important issue. Current fertility preservation options in BC survivors range from well-established standard techniques to experimental or investigational interventions. Among the standard options, random-start ovarian stimulation protocol represents a new technique, which significantly decreases the total time of the in vitro fertilisation cycle. However, in patients with oestrogen-sensitive tumours, stimulation protocols using aromatase inhibitors are currently preferred over tamoxifen regimens. Cryopreservation of embryos and oocytes are nowadays deemed the most successful techniques for fertility preservation in BC patients. GnRH agonists during chemotherapy represent an experimental method for fertility preservation due to conflicting long-term outcome results regarding its safety and efficacy. Cryopreservation of ovarian tissue, in vitro maturation of immature oocytes and other strategies are considered experimental and should only be offered within the context of a clinical trial. An early pretreatment referral to reproductive endocrinologists and oncologists should be suggested to young BC women at risk of infertility, concerning the risks and benefits of fertility preservation options.
本综述的目的是分析年轻乳腺癌(BC)女性生育力保存的当前选择。由于癌症治疗的改善和生育推迟,BC幸存者的数量不断增加,生育力保存似乎是一个重要问题。BC幸存者目前的生育力保存选择范围从成熟的标准技术到实验性或研究性干预措施。在标准选择中,随机启动卵巢刺激方案是一种新技术,可显著缩短体外受精周期的总时间。然而,对于雌激素敏感肿瘤患者,目前使用芳香化酶抑制剂的刺激方案优于他莫昔芬方案。胚胎和卵母细胞冷冻保存如今被认为是BC患者生育力保存最成功的技术。化疗期间使用促性腺激素释放激素(GnRH)激动剂是一种生育力保存的实验方法,因为其安全性和有效性的长期结果存在矛盾。卵巢组织冷冻保存、未成熟卵母细胞的体外成熟及其他策略被认为是实验性的,仅应在临床试验的背景下提供。对于有不孕风险的年轻BC女性,应建议她们尽早转诊至生殖内分泌学家和肿瘤学家处,了解生育力保存选择的风险和益处。